Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren't just aesthetically pleasing. They also play ...
Spotlight Therapeutics, a Bay Area biotech company that raised $66 million from investors, including GV, has shut down.
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic diseases to ...
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
Recent innovations in DNA-modifying will revolutionize the treatment of many diseases and prompt crucial discussions.
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Shares of CRISPR Therapeutics (NASDAQ:CRSP) were on track to snap six straight days of gains, as the stock fell more than 4% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback